Literature DB >> 12619096

Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas.

Rita Nizzoli1, Cecilia Bozzetti, Pellegrino Crafa, Nadia Naldi, Annamaria Guazzi, Beatrice Di Blasio, Roberta Camisa, Stefano Cascinu.   

Abstract

Detection of HER-2/neu alterations is increasingly used in breast cancer patients for therapeutic purposes. This study examines the reliability of HER-2/neu immunocytochemical assessment on 66 cytospin smears obtained by fine-needle aspiration biopsy from breast cancer patients. Results were compared with those obtained by both fluorescence in situ hybridization (FISH) on fine-needle aspirate (FNA) and immunohistochemistry (IHC) on matched histologic section. Concordance between immunocytochemistry (ICC) and FISH was 78% and between ICC and IHC was 84%. Discordance mainly concerned seven unamplified cases that resulted positive by ICC and four cases scored negative by IHC but positive by ICC. Simultaneous assessment of HER-2/neu by ICC, IHC, and FISH was available in 24 cases; the concordance was 75%. In this study, the false positivity of immunocytochemical technique represents the major criticism. In our experience, FISH remains the most objective and powerful technique for HER-2/neu assessment on breast cancer FNAs. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12619096     DOI: 10.1002/dc.10257

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  6 in total

1.  Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma.

Authors:  H Sartelet; E Lagonotte; M Lorenzato; I Duval; C Lechki; C Rigaud; J Cucherousset; A Durlach; O Graesslin; P Abboud; M Doco-Fenzy; C Quereux; B Costa; M Polette; J-N Munck; P Birembaut
Journal:  J Clin Pathol       Date:  2005-08       Impact factor: 3.411

2.  Determination of HER-2 status on FNAC material from breast carcinomas using in situ hybridization with dual chromogen visualization with silver enhancement (dual SISH).

Authors:  Elsa Beraki; Torill Sauer
Journal:  Cytojournal       Date:  2010-10-11       Impact factor: 2.091

3.  MicroRNA analysis of breast ductal fluid in breast cancer patients.

Authors:  Luisa Matos Do Canto; Catalin Marian; Shawna Willey; Mary Sidawy; Patricia A Da Cunha; Janice D Rone; Xin Li; Yuriy Gusev; Bassem R Haddad
Journal:  Int J Oncol       Date:  2016-03-10       Impact factor: 5.650

4.  Comparison of Immunocytochemistry and Immunohistochemistry on Breast Carcinoma: A Boon or a Bane?

Authors:  Kempula Geethamala; Venkataramappa Srinivasa Murthy; Bangalore Ramalingiah Vani; Madireddi Sudha Rao; Malugnalli Uddappa Thejaswini; Krishnarajapet Padmanabha Padmaja
Journal:  J Lab Physicians       Date:  2017 Jan-Mar

5.  HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens.

Authors:  Rieko Nishimura; Nami Okamoto; Masakazu Satou; Kenta Kojima; Shinichi Tanaka
Journal:  Diagn Cytopathol       Date:  2016-01-22       Impact factor: 1.582

6.  Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections.

Authors:  Rieko Nishimura; Nami Okamoto; Masakazu Satou; Kenta Kojima; Shinichi Tanaka; Natsumi Yamashita
Journal:  Breast Cancer       Date:  2016-01-08       Impact factor: 4.239

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.